PACB - パシフィック・バイオサイエンシズ・オブ・カリフォルニア （Pacific Biosciences of California Inc.） パシフィック・バイオサイエンシズ・オブ・カリフォルニアPACBのチャート
PACBの企業情報
| symbol | PACB |
|---|---|
| 会社名 | Pacific Biosciences of California Inc （パシフィック・バイオサイエンシズ・オブ・カリフォルニア） |
| 分野（sector） | Capital Goods 資本財（工業製品） |
| 産業（industry） | Biotechnology: Laboratory Analytical Instruments |
| 業種 | 先端医療機器_テクノロジ― 医療関連（Health Care） |
| 概要 | 事業概要 パシフィック・バイオサイエンシズ（Pacific Biosciences Inc.）は、科学者が遺伝的に複雑な問題を解決するのに役立つシーケンシングシステムを設計、開発、製造する。同社は遺伝子解析のための統合プラットフォームの開発、製造、販売に従事する。同社の単一分子、リアルタイム（SMRT）技術は、生物学的プロセスの単一分子、リアルタイム検出を可能にする。同社はSMRT細胞、PhospholinkedヌクレオチドおよびPacBio RS IIおよびSequel装置を提供する。同社のSMRT技術は、DNAポリメラーゼによって作動されるDNA複製の自然なプロセスを利用することによってリアルタイムで起こるデオキシリボ核酸（DNA）合成の観察を可能にする。同社のリン酸化されたヌクレオチドは、塩基ではなくヌクレオチドのリン酸鎖に結合した蛍光色素を有する。PacBio RS IIおよびSequel機器には、光学機器、自動液体ハンドリング、タッチスクリーン制御インターフェース、コンピューターハードウェアとソフトウェアが含まれる。 パシフィック・バイオサイエンシズ・オブ・カリフォルニアは、米国のバイオ研究会社。遺伝子解析のための技術を開発、製造、販売する。ナノファブリケ―ション、生化学、分子生物学、表面の化学的性質と光学の発展を組み合わせることで、一回の分子反応で生体分子のリアルタイム分析が可能な単一分子リアルタイム（SMRT）技術プラットフォ―ムを開発した。 |
| 本社所在地 | 1305 O'Brien Drive Menlo Park CA 94025 USA |
| 代表者氏名 | Michael W. Hunkapiller マイケル・W・ハンカピラー |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO） |
| 電話番号 | +1 650-521-8000 |
| 設立年月日 | 36708 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2010年 |
| 従業員数 | 456人 |
| url | www.pacb.com |
| nasdaq_url | https://www.nasdaq.com/symbol/pacb |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -80.57800 |
| 終値（lastsale） | 4.39 |
| 時価総額（marketcap） | 579225182.45 |
| 時価総額 | 時価総額（百万ドル） 639.50650 |
| 売上高 | 売上高（百万ドル） 89.42000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 590.13650 |
| 当期純利益 | 当期純利益（百万ドル） -89.50200 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Pacific Biosciences of California revenues decreased 9% to $40.9M. Net loss decreased 5% to $46.7M. Revenues reflect Product revenue decrease of 8% to $34.8M Service and other revenue decrease of 14% to $6.2M. Lower net loss reflects Research and development - Balancing val decrease of 8% to $27.5M (expense) Other Sales general and administrative decrease of 3% to $25.1M (expense). |
PACBのテクニカル分析
PACBのニュース
Digital Genome Market Analysis by Potential Revenue | Illumina, PerkinElmer, Pacific Biosciences of California 2020/11/27 14:09:35 OpenPR
Engaged in development of digital genome, owing to greater future prospects of digital genome in the detection of chronic and infectious disease, birth anomalies, drug discovery & development, and diverse clinical applications. Also, market players are adopting inorganic growth strategies
This Is What Hedge Funds Bought And Sold In Q3: Complete 13F Summary 2020/11/17 03:20:00 Zero Hedge
This Is What Hedge Funds Bought And Sold In Q3: Complete 13F Summary Tyler Durden Mon, 11/16/2020 - 22:20 While we live in a time when the holdings of the top 20 Robinhood "investors" have far more information value for markets and other traders than a glimpse into what hedge funds are doing, not in the least because retail investors are outperforming both the S&P500 and hedge funds 10-to-1… ... unfortunately there is still no regulatory requirement for even superstar retail investors to disclose their holdings, which is why we have to be satisfied with the quarterly 13-F publication spectacle, which just concluded today, and which revealed that even as tech stocks suffered two correction shakeouts since early September, hedge funds mostly stuck with the "safety" of tech stocks during the third quarter heading into the election, even as some hedge funds trimmed Amazon.com as the dominant e-commerce platform thrived amid a pandemic-fueled surge in online shopping, while others sold Netflix Courtesy of Bloomberg, below is a snapshot of what some of the most prominent tech stock additions as disclosed by today's barrage of 13F filings: Coatue Management doubled its holdings of Tesla in the three months ended Sept. 30, making the electric-vehicle maker its second-biggest publicly disclosed holding.
The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations 2020/11/13 12:40:10 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 12) ALX Oncology Holdings Inc (NASDAQ: ALXO ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Denali Therapeutics Inc (NASDAQ: DNLI ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Fate Therapeutics Inc (NASDAQ: FATE ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) (announced preclinical data supporting evaluation of FPA157 as a novel immunomodulator with the potential to remove Treg-mediated immune suppression in solid tumors) Generation Bio Co (NASDAQ: GBIO ) Guardant Health Inc (NASDAQ: GH ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Inspire Medical Systems Inc (NYSE: INSP ) Insulet Corporation (NASDAQ: PODD ) Kodiak Sciences Inc (NASDAQ: KOD ) (announced presentation of clinical study data on its investigational therapy KSI-301 in retinal disorders) Kura Oncology Inc (NASDAQ: KURA ) MannKind Corporation (NASDAQ: MNKD ) Myokardia Inc (NASDAQ: MYOK ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Oncorus Inc (NASDAQ: ONCR ) OncoSec Medical Inc (NASDAQ: ONCS ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Repligen Corporation (NASDAQ: RGEN ) Shockwave Medical Inc (NASDAQ: SWAV ) Spero Therapeutics Inc (NASDAQ: SPRO ) Tcr2 Therapeutics Inc (NASDAQ: TCRR ) (announced its third-quarter results) Twist Bioscience Corp (NASDAQ: TWST ) Ultragenyx Pharmaceutical Inc (NASDAQ: RARE ) Veracyte Inc (NASDAQ: VCYT ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov.
Pacific Biosciences of California prices equity offering (NASDAQ:PACB) 2020/11/11 10:44:27 Seeking Alpha
Pacific Biosciences of California (NASDAQ:PACB) has priced underwritten public offering of ~7.4M shares at $14.25/share, for gross proceeds of ~$86.9M. The
Pacific Biosciences of California (NASDAQ:PACB) Stock Price Up 5.2% 2020/10/24 11:50:47 The Olympia Report
Pacific Biosciences of California (NASDAQ:PACB) shares shot up 5.2% during mid-day trading on Thursday . The stock traded as high as $13.86 and last traded at $13.77. 2,846,571 shares were traded during trading, an increase of 11% from the average session volume of 2,570,063 shares. The stock had previously closed at $13.09. Several analysts have […]
Pacific Biosciences (PACB) Up 8.1% Since Last Earnings Report: Can It Continue? 2020/06/05 15:31:47 Zacks Investment Research
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pacific Biosciences (PACB) Q1 Earnings Surpass Estimates 2020/05/08 06:57:00 Zacks Investment Research
Pacific Biosciences (PACB) saw revenue growth in the Service and Other segment in Q1.
Will Pacific Biosciences of California (PACB) Report Negative Earnings Next Week? What You Should Know 2020/04/29 16:34:25 Zacks Investment Research
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pacific Biosciences of California (PACB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release 2020/04/24 16:30:34 Zacks Investment Research
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pacific Biosciences' Sequel II Gets Acquired by inqaba biotec 2020/04/21 11:22:00 Zacks Investment Research
Pacific Biosciences' (PACB) new development is likely to boost the company's flagship platform, the Sequel system.
Pacific Biosciences (PACB) Up 8.1% Since Last Earnings Report: Can It Continue? 2020/06/05 15:31:47 Zacks Investment Research
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pacific Biosciences (PACB) Q1 Earnings Surpass Estimates 2020/05/08 06:57:00 Zacks Investment Research
Pacific Biosciences (PACB) saw revenue growth in the Service and Other segment in Q1.
Will Pacific Biosciences of California (PACB) Report Negative Earnings Next Week? What You Should Know 2020/04/29 16:34:25 Zacks Investment Research
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pacific Biosciences of California (PACB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release 2020/04/24 16:30:34 Zacks Investment Research
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.